Advisors lead their fields in patent law, nutraceuticals & ethnobotany VANCOUVER, BC, Feb. 1, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the appointment of three key advisors to its new Bioscience Advisory Board.


Previous articlePsychedelic or Not: Of Mice, 5-HT2A Agonists, and Head Shakes
Next articleSmall Pharma Reports Fiscal Third Quarter 2021 Highlights